更新于：2024-11-01

Erythromycin/Isotretinoin

红霉素/异维甲酸

更新于：2024-11-01

概要

概要

基本信息

药物类型

小分子化药

别名

Isotrexin

靶点

50S subunit x RARs

作用机制

50S subunit抑制剂(50S核糖体亚基抑制剂)、RARs激动剂(维甲酸受体家族激动剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

GlaxoSmithKline UK Ltd.

在研机构

GlaxoSmithKline UK Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

德国 (2008-04-05)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C37H67NO13

InChIKeyULGZDMOVFRHVEP-RWJQBGPGSA-N

CAS号114-07-8

查看全部结构式(2)

关联

100 项与红霉素/异维甲酸相关的临床结果

登录后查看更多信息

100 项与红霉素/异维甲酸相关的转化医学

登录后查看更多信息

100 项与红霉素/异维甲酸相关的专利（医药）

登录后查看更多信息

项与红霉素/异维甲酸相关的文献（医药）

2016-12-01·Contact Lens and Anterior Eye3区 · 医学

Effects of topical acne treatment on the ocular surface in patients with acne vulgaris

3区 · 医学

Article

作者: Çölgeçen, Emine ; Gürdal, Canan ; Bayhan, Hasan Ali ; Aslan Bayhan, Seray

PURPOSETo assess the ocular side effects during topical retinoid-antibiotic combination treatment in patients with facial acne vulgaris.METHODSForty-three patients applying topical isotretinoin+erythromycin combination (isotrexin gel, GlaxoSmithKline) once daily for the treatment of acne vulgaris were enrolled. Full ophthalmologic examination, Schirmer test (with topical anesthesia), fluorescein break-up time (BUT), corneal fluorescein staining and tear osmolarity measurement with the TearLab system (TearLab Corporation) were carried out before and at the end of the first month of the treatment. For evaluation of symptoms participants completed the ocular surface disease index (OSDI) questionnaire at each visit.RESULTSThe mean age of the patients was 23.16±3.03 (18-30) years. Mean tear osmolarity increased significantly from 282.09±8.95 mOsm/L at baseline to 300.39±16.65 mOsm/L after the treatment (p<0.001). BUT decreased from an average of 11.93±1.12s at baseline to 6.65±3.03s at the end of the first month (p<0.001). The OSDI score worsened significantly (5.41±3.65 vs 21.53±12.95, p<0.001) and punctate epitheliopathy was seen in 51% of eyes after the treatment. The average Schirmer values were 13.09±1.90 and 12.41±2.44mm/5min before and at the end of the first month of the treatment, respectively (p=0.117).CONCLUSIONSThe findings of this study indicate that topical retinoid-antibiotic combination treatment causes significant signs and symptoms of dry eye. Patients receiving topical treatment for acne should be evaluated regularly to ensure the timely detection and treatment of pathologic signs on the ocular surface.

2002-01-01·Journal of Dermatological Treatment4区 · 医学

Clinical evaluation of Double Strength Isotrexin™ versus Benzamycin ® in the topical treatment of mild to moderate acne vulgaris

4区 · 医学

Article

作者: Davies, HD ; Donald, AE ; Boorman, GC ; Marazzi, P

BACKGROUNDTopical retinoid therapy has been shown to be an effective means of treating both the inflammatory and non-inflammatory lesions of acne vulgaris.AIMTo assess the efficacy and safety of the test product, a gel containing isotretinoin 0.1% w/w and erythromycin 4.0% w/w, with a currently used and effective treatment for mild to moderate acne vulgaris, a gel containing benzoyl peroxide 5.0% w/w and erythromycin 3.0% w/w.METHODSThis multi-centre, single-blind (investigator blind), parallel group study compared the efficacy and safety of isotretinoin/erythromycin gel (Double Strength Isotrexin) once daily against benzoyl peroxide/erythromycin gel (Benzamycin twice daily in the topical treatment of mild to moderate acne vulgaris. Patients (n = 188) with a history (mean duration 3.3 years) of facial acne vulgaris and with 15-100 inflammatory lesions and/or 15-100 non-inflammatory lesions, but not more than three nodulocystic lesions, were included. At baseline and weeks 2, 4, 8 and 12, the investigator assessed efficacy (total number and severity of inflammatory and non-inflammatory lesions and acne grade) while subjective global change assessments of facial acne from baseline and symptom-specific skin tolerance were assessed by the patient. The investigator recorded an overall global assessment of skin tolerability at week 12. Adverse events were recorded throughout.RESULTSThe treatments were comparable with regard to their effects on inflammatory and non-inflammatory lesions and acne grade. Few adverse events were considered to be treatment-related. Both the isotretinoin/erythromycin and benzoyl peroxide/erythromycin gels were generally well tolerated. Compliance was better with the isotretinoin/erythromycin gel, which had the advantages of not requiring mixing or storage in a refrigerator, and was applied once rather than twice daily.CONCLUSIONSIsotretinoin/erythromycin gel given only once daily showed comparable efficacy with benzoyl peroxide/erythromycin given twice daily in the treatment of mild to moderate acne vulgaris of the face.

1999-01-01·Dermatology4区 · 医学

A Placebo-Controlled Clinical Trial to Compare a Gel Containing a Combination of Isotretinoin (0.05%) and Erythromycin (2%) with Gels Containing Isotretinoin (0.05%) or Erythromycin (2%) alone in the Topical Treatment of Acne vulgaris

4区 · 医学

Article

作者: Goode, K. ; Glass, D. ; Cunliffe, W. J. ; Stables, G. I. ; Boorman, G. C.

Purpose: To compare the clinical benefit of isotretinoin (0.05%) and erythromycin (2%) gels alone and in combination (Isotrexin™) in acne patients. Procedure: The study was a randomised placebo-controlled trial in acne patients who should benefit from topical therapy. Results: All treatment groups except placebo produced a time-related reduction in lesion counts, with the combined therapy producing the largest mean decrease. Between-group comparisons showed several significant differences. Conclusion: Isotrexin was significantly better than placebo at all time points for inflamed and total lesions, and was better than isotretinoin at week 4. Side-effects were minimal.

100 项与红霉素/异维甲酸相关的药物交易

登录后查看更多信息